NAEC Meeting Minutes - February 28, 2005

The National Advisory Eye Council (NAEC) convened for its one hundred ninth meeting at 10:00 a.m. on Monday, February 28, 2005, in the Hyatt Regency Bethesda, Bethesda, Maryland. The Director of the National Eye Institute (NEI), Paul A. Sieving, M.D., Ph.D., presided as Chair of the Council. The meeting was open to the public from 10:00 a.m. until 1:00 p.m., and from 7:00 p.m. until 9:00 p.m. The meeting was closed for the review of grant applications from 2:30 p.m. until 5:00 p.m. Attachment A provides a roster of Council members.

TOP

COUNCIL MEMBERS PRESENT:

Dr. Ruben Adler
Dr. Roy W. Beck
Dr. Suraj P. Bhat
Dr. Eileen E. Birch
Dr. Gunilla Haegerstrom-Portnoy
Dr. Barrett G. Haik
Dr. Lenworth Johnson
Dr. Todd P. Margolis
Dr. Earl L. Smith
Dr. Lois E. Smith
Dr. Mriganka Sur
Dr. Janey Wiggs
Dr. Marco A. Zarbin (Ex Officio)

COUNCIL MEMBER ABSENT:

Lt. Col. J. Brian Reed (Ex Officio)

TOP

NEI STAFF PRESENT:

Ms. Louise M. Amburgey
Dr. Houmam Araj
Dr. Deborah Carper
Dr. Hemin R. Chin
Dr. Mary Frances Cotch
Ms. Janet Craigie
Mr. William W. Darby
Ms. Chris A. Davis
Ms. Linda Dingle
Dr. Peter A. Dudley
Ms. Judy Duff
Mr. Donald F. Everett
Dr. Richard S. Fisher
Dr. Ralph J. Helmsen
Dr. Chyren Hunter
Ms. Tina Jones
Mr. J. Kevin Keating
Dr. Natalie Kurinij
Ms. Marilyn Laurie
Dr. Ellen S. Liberman
Dr. Jack A. McLaughlin
Dr. Loré Anne McNicol
Ms. Kathleen Moy
Dr. Michael D. Oberdorfer
Dr. Samuel Rawlings
Dr. Maryann Redford
Dr. Jean Paul SanGiovanni
Dr. Grace L. Shen
Ms. Karen Robinson Smith
Dr. Annie E. Schaffner
Dr. Paul Sieving
Ms. Judy Stein
Ms. Mary Frances Tillman
Ms. Karen Tolson
Dr. Santa Tumminia
Mr. John Whitaker

TOP

OTHER NATIONAL INSTITUTES OF HEALTH (NIH) STAFF PRESENT:

Dr. David Armstrong, Center for Scientific Review (CSR)
Dr. Michael Chaitin, CSR
Dr. Arlene Chiu, National Institute of Biomedical Imaging and Bioengineering
Ms. Betsey Dean, Office of Science Policy and Planning, Office of the Director, NIH
Dr. Christine Livingston, CSR
Dr. Michael Steinmetz, CSR
Dr. Jerome Wujek, CSR

TOP

OTHER FEDERAL GOVERNMENT STAFF PRESENT:

Dr. Wylie Chambers, Food and Drug Administration

TOP

MEMBERS OF THE GENERAL PUBLIC PRESENT AT THE OPEN SESSION:

Ms. Joanne Engle, Association for Eye and Vision Research
Dr. Israel Goldberg, Health Research Associates
Mr. James Jorkasky, Alliance for Eye and Vision Research
Ms. Nicole A. McPherson, Uniformed Services University of the Health Sciences
Ms. Eileen Resnick, Society for Women’s Health Research
Ms. Hollie E. Stephenson, Association of Independent Research Institutes
Ms. Helen M. Viksnins, American Academy of Optometry
Dr. John Whitener, American Optometric Association

MONDAY, FEBRUARY 28, 2005

OPEN PORTION OF THE MEETING

TOP

CALL TO ORDER AND OPENING REMARKS

Dr. Paul A. Sieving, Director, NEI, and Chairman of the Council, called the meeting to order and welcomed the Council members to the one hundred ninth meeting of the National Advisory Eye Council.

Dr. Sieving introduced four new members of the council:

Dr. Gunilla Haegerstrom-Portnoy, is an O.D., Ph.D. clinician scientist who serves as the Associate Dean for Academic Affairs, as well as the Associate Dean for Clinical Sciences, at the School of Optometry at the University of California, Berkeley. Dr. Haegerstrom-Portnoy is an internationally-recognized expert on psychophysics and the evaluation of color vision. In addition to her scientific accomplishments, Dr. Haegerstrom-Portnoy is active in public policy issues, and last year was recognized with the Glenn A. Fry Award from the American Academy of Optometry.

Dr. Lenworth N. Johnson is an M.D. Professor of Ophthalmology and Neurology, the Vice-Chairman of the Department of Ophthalmology, and the Director of the Neuro-Ophthalmology Service at the University of Missouri. He was Principal Investigator in the NEI-sponsored Ischemic Optic Neuropathy Decompression Trial and its follow-up study, and has published extensively in the area of optic nerve pathology. Dr. Johnson has won many teaching awards, and has frequently been named among The Best Doctors in America. In addition to these scientific and academic pursuits, Dr. Johnson is Chairman of the Ophthalmology Section of the National Medical Association and has written extensively on public policy issues regarding health care disparities.

Dr. Todd P. Margolis is an M.D., Ph.D. clinician scientist who serves as Professor of Ophthalmology and Director of the Francis I. Proctor Institute at the University of California, San Francisco. Dr. Margolis is an expert on herpes simplex virus infections of the cornea, and studies differential gene expression in a transgenic mouse model of HSV latency. We are pleased to welcome him as an official Council member, and thank him for his past ad hoc service.

Dr. Earl L. Smith is an O.D., Ph.D. clinician scientist who is the Dean and Greeman-Petty Professor of Vision Development at the University of Houston, College of Optometry. He is an international expert in the field of amblyopia and psychophysical investigation of visual function. He has been recognized by several research awards, the Glenn A. Fry Award of the American Academy of Optometry, and by many teaching awards, including Educator of the Year from the Texas Optometric Association.

TOP

CONFIDENTIALITY / AVOIDANCE OF CONFLICT OF INTEREST

Dr. Loré Anne McNicol, Director, Division of Extramural Research, NEI, and Executive Secretary of the Council, reviewed NIH policies and procedures regarding confidentiality and avoidance of conflict of interest situations. To avoid conflict of interest, members of federal advisory committees must not participate in the discussion of any application or proposal in which they, their spouse, minor child, close professional associate, or organization has a financial interest or affiliation. The Council members were asked to sign the statement in their table folders, certifying that they were absent during such discussions. She also reminded members that applicants are not to contact Council members directly regarding materials being considered by Council. Any such contacts should be forwarded to the appropriate NEI staff member.

Dr. McNicol introduced a new member of the extramural staff, Dr. Päivi Miskala, who has joined the Collaborative Clinical Research team. Dr. Miskala did her undergraduate work in biology and earned a master’s degree in epidemiology at the University of South Florida. During this period, Dr. Miskala had an opportunity to work at the Jaeb Center for Health Research on ophthalmology clinical trials, including the Optic Neuritis Treatment Trial. She then completed a Ph.D. degree in epidemiology at the Johns Hopkins Bloomberg School of Public Health, with a dissertation for which she conducted a multi-center study to assess the relative contributions of reduced vision and general health to the quality of life in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration or ocular histoplasmosis syndrome. Dr. Miskala served on the Wilmer faculty at Johns Hopkins as a Research Associate, Instructor, and then Assistant Professor of Ophthalmology. Dr. McNicol indicated that the NEI is very pleased to have recruited someone with her high level expertise in epidemiology and biostatistics.

TOP

CONSIDERATION OF MINUTES OF PREVIOUS MEETING

The minutes of the September 9-10, 2004, NAEC meeting were accepted by Council vote.

TOP

FUTURE COUNCIL MEETING DATES

The following dates were previously agreed upon for future Council meetings:

June 9-10, 2005
September 22-23, 2005

Members were asked to continue to keep these dates reserved as they make future plans and obligations. NEI staff has listed possible dates for the Calendar Year 2006 Council meetings in the members’ table folders. Members were asked to look these over and send them with the times they would be available. Dr. McNicol indicated that she will email everyone as soon as the dates are set.

TOP

BUDGET OVERVIEW

Ms. Marilyn Laurie, Budget Officer, NEI, presented an update of the FY2006 President’s Budget. She indicated that a 0.7% increase was recommended for both the NEI ($673.4M vs. $669.1M in FY2005) and the NIH as a whole ($28.8B vs. $28.6B in FY2005), even though other non-defense, non-discretionary programs were held to a flat budget. She reviewed the history of NEI appropriations, and described the process through which the President’s budget is formulated. When NEI contributions to the Roadmap and the Neurosciences Blueprint are excluded from the NEI President’s budget, the funds available for Research Project Grants will actually decline by 0.2% compared with the FY2005 level. Ms. Laurie presented the NEI relative budget distribution among Research Management and Support (RMS) and the Extramural and Intramural Research Programs. There were no changes compared with FY2005: Extramural Research continues to account for 86.5% while Intramural Research is 10.2%. The increase in RMS will not cover the proposed Federal pay raise.

Mr. James F. Jorkasky distributed a press release from the National Association for Eye and Vision Research (NAEVR) advocating the citizens’ budget for the NEI. NAEVR called for a 6% increase, to $711M. This amount would bring the NEI budget to parity with the doubling of the NIH budget in the period 1999-2004.

TOP

EXTRAMURAL BUDGET TRENDS

Dr. McNicol provided an update of the current extramural budget operating plan. As an overview, she indicated that continuing grants will funded at the full recommended levels, that competitive grant budgets would be recommended by the staff on a case-by-case basis, and that there will be few new special funding initiatives. She estimated that the R01-type grant award rate would decrease to 25.2%. This level includes a 2.5% decrease in the number of grants awarded, accompanied by a 19% increase in the number of applications submitted. NEI staff has actively managed past year budgets to in order to minimize the drop in numbers of grants funded. Unfortunately, the soaring application numbers reflect an NIH-wide trend that has had a drastic effect on award rates.

TOP

COUNCIL OPERATING PROCEDURES

Dr. McNicol reminded Council members that at every winter council meeting, the staff reviews the document which outlines our council operating procedures and principles. A copy of this document is available in the table files, and Mr. William Darby, the NEI Grants Management Officer, reviewed its provisions. No changes were proposed. Council voted to accept the FY2005 Council Operating Procedures.

TOP

BIENNIAL ADVISORY COUNCIL REPORT CERTIFYING COMPLIANCE WITH THE NIH POLICY ON INCLUSION GUIDELINES

Dr. McNicol presented a two year overview regarding NEI compliance with the NIH policy on the inclusion of women and minorities in sponsored research. She reviewed the legal and ethical background to the NIH policies in this matter. The law mandates that women and minorities be included in all clinical research studies, and that Phase III clinical trials be designed to permit valid analysis of gender and ethnic subgroups. The NIH is enjoined to support outreach efforts to recruit and retain women, minorities, and their subpopulations in clinical studies. Dr. McNicol presented the NEI strategies in place to encourage compliance with these guidelines. These activities include public education efforts on the NEI web site and in all published funding initiatives; staff training; documentation of grant files; maintenance of a population tracking system, and collaboration with various NIH Offices to secure funds to recruit additional special populations to NEI-funded Phase III clinical trials.

Dr. McNicol presented data regarding the inclusion of women in NEI funded research. In FY2003, 41% of study subjects were women. In FY2004 this rose to 56%. In Phase III clinical trials, in FY2003 60% of subjects were female, and in FY2004 58% were female. She also presented data regarding the inclusion of ethnic subpopulations. African Americans comprised 23% of the individuals in NEI-sponsored clinical research in FY2003, and 20% in FY2004. Other groups were represented at levels comparable to their proportion in the America population. In NEI-sponsored Phase III clinical trials for FY2003 and FY2004, African Americans were 27% and 31% of the totals. This over-representation correlates with the frequency of African American patients in NEI trials studying various aspects of glaucoma and diabetic retinopathy

Council members voted to accept the report as being in compliance.

TOP

NIH POLICY ON ENHANCING PUBLIC ACCESS TO ARCHIVED PUBLICATIONS RESULTING FROM NIH-FUNDED RESEARCH

Dr. McNicol informed Council that Dr. Elias Zerhouni, Director, NIH, has recently announced a new NIH policy designed to facilitate public access to the publications which result from NIH-funded, and taxpayer-supported, research. He has asked that all Institutes and Centers brief their Council regarding the purpose and structure of this new initiative. Dr. McNicol described the process through which grantees will submit manuscripts to PubCentral, a freely-available, on-line database maintained by the National Library of Medicine. Submission is voluntary, and it begins on May 16, 2005. Investigators are requested to submit the final version of peer reviewed articles within twelve months of acceptance. Submission to PubCentral will be accepted in lieu of the requirement that manuscripts be submitted with the investigators’ annual progress report. Additional information is available on the NIH website at http://www.nih.gov/about/publicaccess/index.htm

TOP

CONCEPT CLEARANCE: SYMPOSIUM ON OCULAR EPIDEMIOLOGY

Dr. Natalie Kurinij, Director of the Epidemiology and Clinical Studies Program, presented the concept for a symposium the staff is proposing to hold in the spring of 2006. She indicated that it has been 14 years since the NEI surveyed the state of the field of Ocular Epidemiology. She proposed the use of a cooperative agreement conference grant to permit NEI staff and extramural scientists an opportunity to assess the accomplishments of the past decade and identify future needs in such areas as the incidence and prevalence of eye disease in special populations, the identification of risk factors, the classification and measurement of ocular function, and the application of new statistical methodology.

Council members expressed their enthusiasm for this proposal, indicating that there is a significant need to identify gaps in our knowledge. Members were concerned that the outcomes of the conference be widely communicated to the community at large, and Dr. Kurinij indicated that her plan was to explore having the symposium proceedings published in a major journal.

Council members voted to accept the concept.

TOP

REPORT ON THE NEI DAVID G. COGAN CLINICIAN SCIENTIST SYMPOSUM

Dr. Chyren Hunter, the NEI Training Officer, reviewed the outcome of the symposium held this past December to honor Dr. Cogan’s scientific contributions. The objectives of the symposium were to survey the research being performed by vision clinician scientists, to provide opportunities for networking and providing input for NEI staff, and to tour the NIH. One hundred two clinician scientists attended the meeting. Highlights included a celebration of the life and work of Dr. Cogan, an overview of NIH and NEI translational research and clinical research, scientific presentations, poster sessions, and panel discussions on ways to enhance career development for clinician scientists.

TOP

NANOMEDICINE ROADMAP UPDATE

Dr. Richard Fisher, the Corneal Diseases Program Director, provided an update on NEI participation in the Nanomedicine portion of the NIH Roadmap for Medical Research. He indicated that the goal of the initiative is to uncover novel properties of molecules and nanomachinery in cells, to investigate intracellular biophysics at the nano scale, and to use the knowledge developed to understand cellular properties and design principles.

NEI is the lead institute for this initiative, which aims to fund a set of networked, multidisciplinary Nanomedicine Development Centers. Congress has give NEI Flexible Research Authority to facilitate this process. In FY2004, 81 investigators submitted five page white papers describing their vision for a Center. After review, twenty of these were awarded a $50,000 planning grant to develop their concept. These investigators will meet with the NIH Nanomedicine Working Group team on March 10-11 to further refine the Centers. In April there will be a limited competition Request for Applications that will result in the funding of three to four Centers, with a total budget of $6M. In FY2006, an additional $6M in Roadmap funds will expand the Centers network.

Dr. Fisher informed Council that the NEI will sponsor a pre-ARVO Saturday course on Nanomedicine in order to inform and stimulate the vision research community.

TOP

NIH NEUROSCIENCE BLUEPRINT UPDATE

Dr. Michael Oberdorfer, Director, Director of the Strabismus, Amblyopia, and Vision Processing and Low Blindness and Blindness Rehabilitation Programs gave an overview of activities under the NIH Neuroscience Blueprint. He reviewed the background of this initiative, which started in FY2004. Its purpose is to accelerate the pace of discovery and translation, increasing the benefits to the NIH research investment, and to facilitate cooperation among the 16 Blueprint Institutes and Centers (ICs). The Blueprint began with an inventory of neuroscience efforts. Each IC had a community meeting to prepare these estimates. The Blueprint ICs invest over $4.5B annually in neurosciences research, and the NEI is 4th at the NIH in its neuroscience investment. These inventories are used as the base to determine IC financial contributions to the initiative. Next, a Neuroscience Blueprint Consultants meeting was held to plan outreach to scientific societies and advocacy groups The strategies, agreements, and organizational structure were established, and the Blueprint was launched by Dr. Elias Zerhouni, Director, NIH, at the 2004 annual meeting of the Society for Neuroscience.

Dr. Oberdorfer described the common pool of funds for the initiative, which is based on a percentage of each IC’s inventory level. In FY2005, the contribution will be 0.15%. By FY2009, this figure will rise to 0.6%. Funding initiatives planned for FY2005 include an expansion of the GENSAT gene expression map contract to include mouse models of the sensory systems; a global inventory of neuroscience tools, using PubCentral as a tool to identify and eliminate redundancy; supplements for research training in the Neurobiology of Disease, expansion of the DNA Microarray Consortium to add three to four new sites, and an expansion of the Pediatric MRI of Normal Development through the Lifespan initiative. Initiatives under consideration for FY2006 include core facilities for neuroscience research; three new training initiatives in neuroimaging, computational neuroscience, and translational research; and the Neuromouse Initiative to develop, phenotype, and disseminate gene knockout mouse lines.

In summary, Dr. Oberdorfer stressed that the goals of the Neurosciences Blueprint are to cooperate, coordinate, accelerate, and support research. In response to questions from Council members, Dr. Oberdorfer indicated that the Blueprint IC Directors review all potential initiatives. The initiatives chosen for implementation will be announced through the usual venues, such as the NIH Guide to Grants and Contracts.

TOP

US-INDO COLLABORATIVE RESEARCH WORKSHOP REPORT

Dr. Ellen Liberman, Director of the Lens and Cataract and the Glaucoma and Optic Neuropathies Programs, described this new research initiative. The purpose of the interaction is to promote collaborative exchange between vision scientists in India and the US, centered on unique patient populations for clinical research and on unique research resources for translational research. A series of international meetings will be organized by ARVO and supported through an NEI conference grant.

The first meeting was held in India in February, 2005. The meeting was attended by 22 US scientists and 19 State of India scientists. There was a scientific workshop sponsored by the L. V. Prasad Institute, Hyderabad. The meeting focused on the molecular aspects of genetic eye diseases; the harmonization of clinical measures; translational physiology; and the identification, development, and exchange of research resources. The workshop was followed by site visits to clinical facilities in Hyderabad, Madurai, and Chennai. The second meeting will take place this spring in association with the annual ARVO meeting.

Dr. Liberman indicated that the outcome of these meetings is expected to take the form of a report published in Investigative Ophthalmology and Vision Science. This report would list resources and collaborative research opportunities identified during the conferences. The NEI outcomes are expected to include new grant applications, and new collaborations in the form of subcontracts or consortia on existing grants.

Ms. Joanne Angle, Executive Director, ARVO, indicated that copies of an ARVO press release regarding the US-Indo collaboration were available for Council members, NEI and NIH staff, and guests at the meeting. Council members Dr. Suraj Bhat and Dr. Janey Wiggs commented on their experiences at the meetings. They indicated that there was a very high level of scientific culture and competence in the State of India facilities, and that there is an enormous potential for collaborations to understand the biology of visual disease.

Dr. Leon Ellwein, Associate Director for Applications of Vision Research, NEI, described the political context for the US Indo Collaboration. Both countries have prepared a government-to-government Statement of Intent to collaborate on the expansion of vision research. This document recognizes the strong commitment both countries share to reduce the burden of vision disability and blindness; the high degree of research expertise in basic biology and clinical science in both countries which could make collaboration on an equal footing possible; and the long history of successful research collaboration between India and U.S. scientists and institutions in the prevention of blindness. Dr. Ellwein indicated that he anticipates that the agreement will be signed this summer by Dr. Zerhouni and Dr. Maharaj K. Bhan, Secretary, Department of Biotechnology, Ministry of Science and Technology, State of India.

Council members expressed their enthusiasm for this initiative and predicted that it could play a major role in accelerating the pace of vision research.

TOP

NATIONAL GENOTYPING NETWORK UPDATE

Dr. Hemin Chin, Ocular Genetics Program Director, reviewed recent activities in establishing the National Ophthalmic Disease Genotyping Network. He reminded members the purpose of the Network is to establish an integrated genotype/phenotype database that is publicly accessible to the vision community. The network concept, approved at the February 2004 Council meeting, included national genotyping centers, a database, a repository, and an information center. In order to initiate the Network, an administrative supplements program to enhance diagnostic genotyping of ophthalmic disease was published in December. Awards are expected to be made on May 1. NEI intramural scientists are developing a prototype database and an RFA or contract solicitation will be released in FY2006 to fully implement the Network.

Council members indicated that they were pleased with the progress NEI has shown in developing this important initiative. They indicated that staff should explore efficiencies to avoid large cost increases in future years. They also hoped that there would be a mechanism for investigators to add existing data to the database.

TOP

CLOSED PORTION OF THE MEETING

At 2:30 pm the meeting was closed to the public in accordance with the determination that it was concerned with matters exempt from mandatory disclosure under Sections 552b(c)(4) and 552b(c)(6), Title 5, U.S. Code and Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2).

Council considered research and research training grants. Council members absented themselves from the meeting during discussion of and voting on applications from their own institutions, or other applications in which there was a potential conflict of interest, real or apparent. Members signed a statement to this effect.

The closed portion of the meeting ended at 5:00 pm.

TOP

OPEN PORTION OF THE MEETING

TOP

NEI FUTURE PROGRAM DIRECTIONS AND EXTRAMURAL PRIORITIES

Dr. Ruben Adler presented three issues for open discussions: (1) Dr. Sieving needs to have Council more involved with NEI programs in the time between formal Council meetings, (2) this is a period of budgetary crisis and opportunity; and (3) there is a need to reevaluate how funding priorities should be established. Dr. Adler proposed that Council workgroups be established in order to identify strategic decisions. These groups should examine how R01 funding should be done at a time when the science needs fast action and control and should determine how portfolio balance should be performed in order to identify areas which are over-funded due to hystorical chance.

Drs. Zarbin and Lois Smith agreed that there is a need to identify the strategic imperatives of the NEI before the June allocations. They indicated that a structure needs to be in place before the next Council meeting to have better interactions between Dr. Sieving, the Council members, and the NEI staff. This is critical for Dr. Sieving to be able to realize his vision for the Institute. Dr. Jack A. McLaughlin, Deputy Director, NEI, suggested that staff prepare such an implementation strategy and share it with Council members. Topics should include an on-going portfolio analysis that includes an examination of the science mix and mechanism mix within each NEI extramural scientific subprogram.

Council members supported this suggestion and discussed the types of data and information that would be helpful for such an analysis. Recommendations included:

  • thorough examination of the training portfolio to be certain we are training the right individuals in the right areas of science
  • determining the cost per patient in NEI-funded clinical trials
  • determining the number and scientific field of NEI-supported studies that are published in major scientific journals
  • the proportion of the portfolio involved with translational research
  • the cost and effectiveness of all R01 special initiatives, compared with investigator-initiated research
  • an inventory of the NEI neuroscience investment
  • an identification and prioritization of the most exciting scientific ideas to implement in the Collaborative Clinical Research portfolio
  • explicit discussion of where extramural funds go
  • identify and emphasize those studies that only the NEI can fund

Dr. McLaughlin said that the extramural staff will develop a process or framework for interacting with Council on these issues. He cautioned that broad discussion is more critical than a grant-by-grant analysis of the portfolio. Council needs to identify any parts of the NEI Program which need to be brought into the scientific mainstream.

Council members favored this approach, feeling that the extramural staff already has the resources. Members expressed their dis-inclination to micro-manage portfolios, but do want to find their role in the process, be productive, and have the information necessary to do both. This activity needs to be channeled to guide discussion and assist Dr. Sieving in decision making.

Dr. Sieving requested Council’s assistance in determining the NEI investment in visual neuroscience. The context is that Council input from regarding the topical areas would be extremely valuable. The NIH Neuroscience Blueprint is one of the models to be followed. Dr. Birch indicated that Council must take a large picture and avoid having individuals push their personal research agendas. Dr. Sieving reiterated that there is a need for portfolio analysis, and that there are initiatives on the table such as the Blueprint, which net the NEI more than the Institute contributes. He indicated that the next level of need is on-going input from Council for moving forward in certain areas. For example, genes get us into cell biology and that gets us into the vibrancy of that community in the health of vision research. To accommodate large-scale research, prudence and a forward look at the portfolio are required.

Dr. Sieving adjourned the meeting at 9:00 p.m. on Monday, February 28, 2005.

TOP

CERTIFICATION

I hereby certify that, to the best of my knowledge, the foregoing minutes and attachment(s) are accurate and complete.


Dr. Loré Anne McNicol, Ph.D.
Executive Secretary
National Advisory Eye Council
Director, Division of Extramural Research
National Eye Institute

Paul A. Sieving, M.D., Ph.D.
Chair
National Advisory Eye Council
Director
National Eye Institute

These minutes have been submitted for the approval of the Council. All corrections or notations have been incorporated. A complete, printed copy of the Council minutes, including attachments, may be obtained from:

Ms. Janet L. Craigie
National Eye Institute
Suite 1300
5635 Fishers Lane, MSC 9300
Bethesda, MD 20892-9300
Telephone: (301) 451-2020
FAX: (301) 402-0528
E-mail: craigiej@nei.nih.gov

04/07/2006


Attachment A

NATIONAL ADVISORY EYE COUNCIL
NATIONAL EYE INSTITUTE

TOP

ROSTER

(Terms end 11/30 of the designated year)

Ruben Adler, M.D. (05)
Department of Ophthalmology
600 N Wolfe St Maumenee 519
Johns Hopkins University School Med.
Baltimore MD 21287-9257

Roy W. Beck, M.D., Ph. D. (06)
Jaeb Center for Health Research
Suite 350, 15310 Amberly Drive
Tampa FL 33647

Suraj P. Bhat, Ph.D. (06)
Department of Ophthalmology
Jules Stein Eye Institute
100 Stein Plaza, BH623
Los Angeles CA 90095-7000

Eileen E. Birch, Ph.D. (07)
Retina Foundation of the Southwest
9900 N Central Expressway, Suite 400
Dallas TX 75231

Gunilla Haegerstrom-Portnoy
O.D., Ph.D. (05)
University of California
School of Optometry
419 Minor Hall
Berkeley, CA 94720

Barrett G. Haik, M.D. (07)
Department of Ophthalmology
University of Tennessee
Health Science Center
930 Madison Avenue, Suite 100
Memphis, TN 38163

Lenworth N. Johnson, M.D. (08)
University of Missouri
Department of Ophthalmology Services
One Hospital Drive
Columbia, MO 65212

Todd P. Margolis, M.D., Ph.D. (08)
Professor of Ophthalmology
Director, F. I. Proctor Foundation
95 Kirkham Street
San Francisco, CA 94122

Earl L. Smith, III, O.D., Ph.D. (08)
University of Houston
College of Optometry
505 J. Davis Armistead Building
Houston, TX 77204

Lois E. H. Smith, M.D., Ph.D. (06)
Department of Ophthalmology
Harvard Medical School
300 Longwood Ave
Boston MA 02115

Mriganka Sur, Ph.D. (07)
Department of Brain & Cognitive Science
Massachusetts Institute of Technology
45 Carleton Street, E25-235
Cambridge, MA 02139

Janey L. Wiggs, M.D., Ph.D. (06)
Department of Ophthalmology
Massachusetts Eye and Ear Infirmary
243 Charles Street
Boston MA 02114

Department of Defense Representative
Lt. Col. J. Brian Reed, M.D.
Chief, Vitreoretinal and Uveitis Services
Wilford Hall Medical Center
Lackland Air Force Base, TX 78236

Department of Veterans Affairs Representative
Marco Z. Zarbin, M.D., Ph.D.
New Jersey Veterans Admin. Hospital
Newark, NJ 07103

Ex Officio Members
Mike Leavitt
Secretary
Department of Health & Human Services
Washington, DC 20201

Elias A. Zerhouni, M.D.
Director
National Institutes of Health
Bethesda, MD 20892

Chair
Paul A. Sieving, M.D., Ph.D.
Director
National Eye Institute
National Institutes of Health
Bethesda MD 20892

Executive Secretary
Loré Anne McNicol, Ph.D.
Director
Division of Extramural Research
National Eye Institute
National Institutes of Health
Bethesda, MD 20892